STOCK TITAN

Lyell Immunopharma, Inc. - LYEL STOCK NEWS

Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.

Lyell Immunopharma, Inc. (NYSE: LYEL) is a clinical-stage biotechnology company developing novel T-cell therapies for solid tumors and hematologic malignancies through proprietary genetic/epigenetic reprogramming technologies. This page serves as the definitive source for verified company announcements, research breakthroughs, and regulatory developments.

Investors and researchers will find timely updates on Lyell's innovative pipeline including CAR T-cell candidates LYL797 and LYL119, tumor-infiltrating lymphocyte therapy LYL845, and dual-targeting IMPT-314 from the ImmPACT Bio acquisition. Our curated news collection covers essential developments across three key areas:

Clinical Trial Milestones: Phase 1/2 updates, patient enrollment progress, and safety/efficacy data disclosures
Research Innovations: Peer-reviewed study publications, ASCO/SITC presentations, and new patent filings
Strategic Developments: Manufacturing partnerships, leadership appointments, and regulatory pathway updates

Bookmark this page for direct access to Lyell's official press releases, SEC filings, and scientifically validated progress reports. Check regularly for updates on technologies addressing T-cell exhaustion and improving durable response rates in cancer immunotherapy.

Rhea-AI Summary

Lyell Immunopharma has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845, a tumor infiltrating lymphocyte (TIL) therapy utilizing Lyell’s proprietary Epi-R technology. This trial will focus on patients with relapsed or refractory melanoma, expanding later to include non-small cell lung cancer and colorectal cancer. Initial data presentation is anticipated in 2024. This marks Lyell's second product candidate to receive IND clearance within the last year, showcasing progress in its mission to develop curative T-cell therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.61%
Tags
none
-
Rhea-AI Summary

Lyell Immunopharma (LYEL) announced its participation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) with five accepted abstracts highlighting new preclinical data. This data focuses on T-cell reprogramming technologies incorporated in LYL119, an investigational ROR1 targeting CAR T-cell therapy. The findings aim to enhance T cell functionality and combat exhaustion in solid tumors, showcasing Lyell's efforts in advancing its therapeutic pipeline to improve patient outcomes in adoptive cell therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
conferences clinical trial
-
Rhea-AI Summary

Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced the appointment of Rahsaan W. Thompson as chief legal officer, enhancing its executive management team. Thompson, an industry veteran with over 20 years of experience in corporate law, previously served at Gritstone bio and Actelion Pharmaceuticals. CEO Liz Homans emphasized Thompson's expertise as a boon for advancing clinical developments targeting solid tumors. Lyell is dedicated to curative cell therapies and is applying innovative reprogramming technologies to improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.08%
Tags
management
Rhea-AI Summary

Lyell Immunopharma (Nasdaq: LYEL) announces the presentation of a poster at the ESMO Congress 2022 on the Phase 1 trial design for LYL797, a CAR T-cell therapy aimed at treating solid tumors. This innovative therapy utilizes Lyell’s Gen-R™ and Epi-R™ technologies to enhance T-cell functionality against challenges like exhaustion. The trial targets patients with advanced solid tumors, including triple-negative breast cancer and non-small cell lung cancer. The poster session occurred on September 12, 2022, in Paris, providing insights into Lyell's commitment to curative cell therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.96%
Tags
none
-
Rhea-AI Summary

Lyell Immunopharma (Nasdaq: LYEL) announced that its senior management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 1:05 p.m. ET. The event will focus on the company’s innovative approaches to T-cell reprogramming aimed at treating solid tumors.

A live webcast can be accessed via the investor relations section of Lyell's website, with a replay available for 90 days post-presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
conferences
-
Rhea-AI Summary

Lyell Immunopharma reported significant financial updates for Q2 2022, with revenue climbing to $35.7 million, a notable increase from $2.6 million in Q2 2021. This surge is attributed to a mutual agreement with GSK for a hematological cancer research initiative. Despite a net loss of $36.3 million, an improvement from $62.6 million in the prior year, Lyell's cash position remains strong at $787 million, expected to fund operations through 2025. The company continues to advance its clinical pipeline, focusing on overcoming T-cell exhaustion in solid tumor therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.32%
Tags
Rhea-AI Summary

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14 at 10:40 AM PT. A live webcast of the event will be available on the company’s website, with a replay accessible for 90 days afterward. Lyell focuses on developing curative cell therapies for solid tumors and utilizes proprietary technologies to enhance T-cell functionality. For more information, visit www.lyell.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
-
Rhea-AI Summary

Lyell Immunopharma reported a first-quarter net loss of $68.1 million for Q1 2022, up from $55.0 million in Q1 2021. The company holds $838 million in cash and marketable securities, expected to cover operations through 2025. Lyell advanced two products into Phase 1 clinical development and plans to submit INDs for LYL845 and LYL331 later this year. R&D expenses decreased to $35.8 million, while G&A expenses rose sharply to $34.4 million, driven by stock-based compensation and litigation costs. Upcoming presentations at ASGCT and AACR are expected to highlight advancements in their cell therapy pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11%
Tags
-
Rhea-AI Summary

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in T-cell reprogramming, announced participation in the BofA Securities 2022 Healthcare Conference on May 11 at 5:20 pm PT. The management team will engage in a fireside chat that can be accessed via a live webcast on the company's investor relations page. A replay will be available for 90 days after the event. Lyell focuses on overcoming challenges in adoptive T-cell therapy, utilizing proprietary technologies Gen-R and Epi-R to enhance T-cell functionality for combating solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
conferences
Rhea-AI Summary

Lyell Immunopharma (Nasdaq: LYEL) announced two abstracts accepted for poster presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy, from May 16 to May 19, 2022. The presentations will showcase preclinical data on LYL797 and LYL132, both in Phase 1 trials, focusing on Gen-R and Epi-R technologies that enhance T-cell performance against solid tumors. LYL797 targets ROR1-positive cancers, while LYL132 targets NY-ESO-1 expressing tumors. The aim is to improve T-cell durability and anti-tumor effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences clinical trial
Lyell Immunopharma, Inc.

Nasdaq:LYEL

LYEL Rankings

LYEL Stock Data

128.01M
227.59M
13.73%
65.93%
2.77%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO